Trial Profile
A randomized phase II study of gemcitabine/cisplatin with or without cetuximab to evaluate the efficacy in patients with locally advanced or metastatic EGFR [epidermal growth factor receptor]-EGFR-positive pancreatic cancer. SpaCe trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms SPaCe-01
- 11 Oct 2007 New trial record.